← All trials
NCT06589245
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2025
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Sep 19, 2024
- Last posted
- Nov 11, 2024
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KansasLead sponsor
- University of KansasOfficial
- National Institutes of Health (NIH)Collaborator
- University of KansasSponsor investigator
- University of PittsburghCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.